title: Cytocompatibility of the ready-to-use bioceramic putty repair cement iRoot BP Plus with primary human osteoblasts.
abstract: OBJECTIVE
  To verify the in vitro cytocompatibility of iRoot BP Plus (iRoot) and to compare it with White ProRoot MTA (MTA).
  
  
  METHODS
  Thirty-six human maxillary incisor root canals were prepared using a step-back flaring technique. The apical 3 mm was resected perpendicular to the long axis at the roots, and root-end cavities were prepared with the aid of an ultrasonic device plus a diamond retrotip with continuous irrigation using water, producing standardized preparations. After that, the root-end cavities were filled with iRoot or MTA, and each root was exposed to cell culture media for 24 or 48 h. Human osteoblast cells were exposed to the extracts thus obtained, and a multiparametric cell viability assay was performed, evaluating mitochondrial activity, membrane integrity and cell density. The results were analysed by one-way analysis of variance, complemented with the Duncan post-test (P < 0.05).
  
  
  RESULTS
  Cells exposed to MTA revealed a cytocompatibility pattern similar to the untreated cells (negative control), at both experimental times (P > 0.05). iRoot, however, promoted a significantly poorer viability than MTA and the control, after 48 h of exposure (P < 0.001). Nevertheless, iRoot did not induce critical cytotoxic effects because cell viability remained higher than 70% of the control group in most tests performed.
  
  
  CONCLUSIONS
  iRoot and MTA were biocompatible and did not induce critical cytotoxic effects.
authors.affiliation: Department of Endodontics, School of Dentistry, Grande Rio University (UNIGRANRIO), Rio de Janeiro, Brazil.
authors.forename: G
authors.initials: G
authors.lastname: De-Deus
authors.forename: A
authors.initials: A
authors.lastname: Canabarro
authors.forename: G G
authors.initials: GG
authors.lastname: Alves
authors.forename: J R
authors.initials: JR
authors.lastname: Marins
authors.forename: A B R
authors.initials: AB
authors.lastname: Linhares
authors.forename: J M
authors.initials: JM
authors.lastname: Granjeiro
mesh_terms: D017607:Aluminum Compounds / Q000494:pharmacology; D001672:Biocompatible Materials / Q000494:pharmacology*; D017610:Calcium Compounds / Q000494:pharmacology*; D002452:Cell Count; D018929:Cell Culture Techniques; D002462:Cell Membrane / Q000187:drug effects; D048430:Cell Shape / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D017077:Culture Media, Conditioned; D004338:Drug Combinations; D006801:Humans; D008928:Mitochondria / Q000187:drug effects; D010006:Osteoblasts / Q000187:drug effects*; D010087:Oxides / Q000494:pharmacology; D012184:Retrograde Obturation / Q000379:methods; D018915:Root Canal Preparation / Q000379:methods; D012823:Silicate Cement / Q000494:pharmacology*; D017640:Silicates / Q000494:pharmacology*; D013997:Time Factors; D046509:Tissue Culture Techniques; D015035:Zinc Oxide-Eugenol Cement / Q000633:toxicity
chemical_list: D017607:Aluminum Compounds; D001672:Biocompatible Materials; D017610:Calcium Compounds; D017077:Culture Media, Conditioned; D004338:Drug Combinations; D010087:Oxides; D017640:Silicates; D015035:Zinc Oxide-Eugenol Cement; C000600177:iRoot BP Plus; C086631:mineral trioxide aggregate; D012823:Silicate Cement; C031293:calcium silicate